ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,416.45
-0.09%
Dow Jones
39,872.99
0.17%
Gold vs US Dollar
2,421.64
-0.20%
Brent Oil
82.435
-1.31%
Bitcoin
69,679.11
-2.48%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Eli Lilly and Co (LLY)

  7. Eli Lilly and Co (LLY) News

Eli Lilly (LLY)

Eli Lilly and Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:LLY
DateTimeSourceHeadlineSymbolCompany
21/05/202421:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/05/202421:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/05/202421:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/05/202421:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/05/202421:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/05/202420:20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:LLYEli Lilly and Co
21/05/202413:00PR Newswire (US)More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failureNYSE:LLYEli Lilly and Co
21/05/202412:18IH Market NewsCalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More NewsNYSE:LLYEli Lilly and Co
16/05/202411:45PR Newswire (US)With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily InsulinNYSE:LLYEli Lilly and Co
15/05/202413:00PR Newswire (US)Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance OfficerNYSE:LLYEli Lilly and Co
09/05/202421:34Edgar (US Regulatory)Form 8-K - Current reportNYSE:LLYEli Lilly and Co
06/05/202416:32PR Newswire (US)Lilly Declares Second-Quarter 2024 DividendNYSE:LLYEli Lilly and Co
30/04/202414:07IH Market NewsFutures Pointing To Roughly Flat Open On Wall StreetNYSE:LLYEli Lilly and Co
30/04/202412:59IH Market NewsU.S. Index Futures Point to Mild Decline Ahead of Key Earnings and Fed Rate DecisionNYSE:LLYEli Lilly and Co
30/04/202412:55IH Market NewsHSBC’s High Profit & CEO Resignation, Santander’s 11% Profit Surge, and More in EarningsNYSE:LLYEli Lilly and Co
30/04/202411:45PR Newswire (US)Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline MomentumNYSE:LLYEli Lilly and Co
17/04/202411:15PR Newswire (US)Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesityNYSE:LLYEli Lilly and Co
16/04/202415:00PR Newswire (US)Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results AnnouncementNYSE:LLYEli Lilly and Co
03/04/202412:12IH Market NewsCal-Maine Surges on Strong Quarterly Performance, Taiwan Earthquake Disrupts Tech Supply Chain, and MoreNYSE:LLYEli Lilly and Co
11/03/202420:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
11/03/202420:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:LLYEli Lilly and Co
10/03/202420:00PR Newswire (US)More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab studyNYSE:LLYEli Lilly and Co
08/03/202411:45PR Newswire (US)U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of DonanemabNYSE:LLYEli Lilly and Co
07/03/202413:00PR Newswire (US)Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity CareNYSE:LLYEli Lilly and Co
05/03/202422:00PR Newswire (US)Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual MeetingNYSE:LLYEli Lilly and Co
21/02/202421:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/02/202421:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/02/202421:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/02/202421:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/02/202421:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
 Showing the most relevant articles for your search:NYSE:LLY

Your Recent History

LSE
BP.
Bp
LSE
TERN
Tern
LSE
POS
Plexus
LSE
SCLP
Scancell
LSE
VAST
Vast Resources
LSE
VAL
Valirx
LSE
YU.
Yu
LSE
GKP
Gulf Keystone Petroleum
LSE
PHE
Powerhouse Energy
LSE
POLX
Polarean Imaging
LSE
THG
Thg
LSE
SYME
Supply@me Capital
LSE
MIN
Minoan
LSE
SOLG
Solgold
LSE
TEK
Tekcapital
LSE
AAZ
Anglo Asian Mining
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved